ES2139607T3 - Anticuerpos monoclonales contra las proteinas e2/ns1 supuestas vhc y procedimientos de utilizacion de estos anticuerpos. - Google Patents

Anticuerpos monoclonales contra las proteinas e2/ns1 supuestas vhc y procedimientos de utilizacion de estos anticuerpos.

Info

Publication number
ES2139607T3
ES2139607T3 ES92920089T ES92920089T ES2139607T3 ES 2139607 T3 ES2139607 T3 ES 2139607T3 ES 92920089 T ES92920089 T ES 92920089T ES 92920089 T ES92920089 T ES 92920089T ES 2139607 T3 ES2139607 T3 ES 2139607T3
Authority
ES
Spain
Prior art keywords
monoclonal antibodies
hcv
procedures
antibodies
antibodies against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92920089T
Other languages
English (en)
Inventor
Smriti U Mehta
Jill E Johnson
Stephen H Dailey
Suresh M Desai
Sushil G Devare
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of ES2139607T3 publication Critical patent/ES2139607T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K16/118—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/82—Hepatitis associated antigens and antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE PRESENTAN ANTICUERPOS MONOCLONALES QUE ESPECIFICAMENTE SE UNEN AL ANTIGENO DEL VIRUS DE LA HEPATITIS C (HCV) E2/NS1. TAMBIEN SE SUMINISTRAN LINEAS CELULARES DE HIBRIDOMAS QUE SEGREGAN ESTOS ANTICUERPOS MONOCLONALES, METODOS PARA USAR ESTOS ANTICUERPOS MONOCLONALES Y EQUIPOS DE ENSAYO PARA ENSAYOS QUE CONTIENEN DICHOS ANTICUERPOS MONOCLONALES.
ES92920089T 1991-08-21 1992-08-21 Anticuerpos monoclonales contra las proteinas e2/ns1 supuestas vhc y procedimientos de utilizacion de estos anticuerpos. Expired - Lifetime ES2139607T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/748,292 US5308750A (en) 1989-12-22 1991-08-21 Monoclonal antibodies to putative HCV E2/NS1 proteins and methods for using same

Publications (1)

Publication Number Publication Date
ES2139607T3 true ES2139607T3 (es) 2000-02-16

Family

ID=25008836

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92920089T Expired - Lifetime ES2139607T3 (es) 1991-08-21 1992-08-21 Anticuerpos monoclonales contra las proteinas e2/ns1 supuestas vhc y procedimientos de utilizacion de estos anticuerpos.

Country Status (9)

Country Link
US (1) US5308750A (es)
EP (1) EP0603307B1 (es)
JP (1) JP3335351B2 (es)
AT (1) ATE185606T1 (es)
AU (1) AU2585092A (es)
CA (1) CA2115923A1 (es)
DE (1) DE69230146T2 (es)
ES (1) ES2139607T3 (es)
WO (1) WO1993004205A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273115B1 (en) * 1986-10-22 1994-09-07 Abbott Laboratories Chemiluminescent acridinium and phenanthridinium salts
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5712087A (en) * 1990-04-04 1998-01-27 Chiron Corporation Immunoassays for anti-HCV antibodies employing combinations of hepatitis C virus (HCV) antigens
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
CA2129733C (en) * 1992-01-31 2006-10-31 James M. Casey Mammalian expression systems for hcv proteins
EP1421951A3 (en) * 1993-05-12 2005-10-05 Chiron Corporation Conserved motif of hepatitis C virus E2/NS1 region
US5824507A (en) * 1994-05-20 1998-10-20 Genelabs Technologies, Inc. Hepatitis G virus and molecular cloning thereof
JP3217600B2 (ja) * 1994-07-12 2001-10-09 株式会社先端生命科学研究所 非ａ非ｂ型肝炎ウイルス関連抗原のイムノアッセイ、それに使用するモノクローナル抗体、およびこの抗体を産生するハイブリドーマ
US20040185061A1 (en) * 1994-07-29 2004-09-23 Innogenetics N.V. Redox reversible HCV proteins with native-like conformation
DK0721505T4 (da) * 1994-07-29 2006-08-14 Innogenetics Nv Rensede hepatitis C-virus-kappeproteiner til diagnostisk og terapeutisk anvendelse
CN1044384C (zh) * 1994-08-25 1999-07-28 中国药品生物制品检定所 抗丙型肝炎病毒抗原单克隆抗体细胞株建立及其单克隆抗体
GB9517926D0 (en) 1995-09-01 1995-11-01 Biocine Spa Binding protein
US6747136B2 (en) 1996-04-19 2004-06-08 Karolinska Innovations Ab Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
US6538114B1 (en) 1996-04-19 2003-03-25 Karolina Innovations Ab Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
US6020195A (en) * 1996-09-18 2000-02-01 Roche Diagnostics Gmbh Antibodies against hepatitis G virus and their use for the diagnostic detection of HGV and as a therapeutic agent
GB9624165D0 (en) * 1996-11-19 1997-01-08 Amdex A S Use of nucleic acids bound to carrier macromolecules
EP0947525A1 (en) 1998-03-27 1999-10-06 Innogenetics N.V. Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue
US7108855B2 (en) * 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
CA2380777C (en) * 1999-07-28 2011-01-04 Chiron Corporation Hepatitis c viral antigen immunoassay detection systems
US6815160B1 (en) 1999-07-28 2004-11-09 Chiron Corporation Hepatitis C viral antigen immunoassay detection systems
AU2002214689A1 (en) * 2000-11-06 2002-05-15 Bio-Tech Imaging, Inc. Method and kits for detecting hepatitis infected cells
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
EP1355947A2 (en) * 2000-12-01 2003-10-29 The Government of the United States of America, as Represented by the Secretary, Department of Health and Human Services Monoclonal antibodies specific for the e2 glycoprotein of hepatitis c virus and their use in the diagnosis, treatment, and prevention of hepatitis c
GB0112652D0 (en) * 2001-05-24 2001-07-18 Inst Of Molecul & Cell Biology Internalisation of virus into cells
US7858752B2 (en) 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
PT2125889E (pt) 2007-02-21 2014-04-15 Univ Massachusetts Anticorpos humanos contra vírus da hepatite c (hcv) e seus usos
EP1978365B1 (en) * 2007-03-16 2010-08-25 Sysmex Corporation Reagent kit and method for measuring HCV antibody
WO2009034190A2 (en) * 2007-09-14 2009-03-19 Genimmune N.V. Affinity tag
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1074422C (zh) * 1987-11-18 2001-11-07 希龙股份有限公司 制备含有hcv表位的分离多肽的方法
KR0185373B1 (ko) * 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
CA2032907C (en) * 1989-12-22 2002-05-14 Richard R. Lesniewski Hepatitis c assay
US5106726A (en) * 1990-02-16 1992-04-21 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV
EP0464287A1 (en) * 1990-06-25 1992-01-08 The Research Foundation for Microbial Diseases of Osaka University Non-A, non-B hepatitis virus genomic cDNA and antigen polypeptide
CA2047792C (en) * 1990-07-26 2002-07-02 Chang Y. Wang Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
CA2049679C (en) * 1990-08-24 2005-06-21 Sushil G. Devare Hepatitis c assay utilizing recombinant antigens

Also Published As

Publication number Publication date
AU2585092A (en) 1993-03-16
CA2115923A1 (en) 1993-03-04
EP0603307A4 (en) 1995-01-18
JPH06510192A (ja) 1994-11-17
WO1993004205A1 (en) 1993-03-04
ATE185606T1 (de) 1999-10-15
JP3335351B2 (ja) 2002-10-15
DE69230146T2 (de) 2000-05-25
DE69230146D1 (de) 1999-11-18
EP0603307A1 (en) 1994-06-29
US5308750A (en) 1994-05-03
EP0603307B1 (en) 1999-10-13

Similar Documents

Publication Publication Date Title
ES2139607T3 (es) Anticuerpos monoclonales contra las proteinas e2/ns1 supuestas vhc y procedimientos de utilizacion de estos anticuerpos.
NZ237666A (en) Hiv envelope (env) polypeptides, antibodies and compositions for treating aids
ES2062971T3 (es) Peptidos de la cubierta de htlv iii.
KR910021474A (ko) 합성 사람 항체 유전자 뱅크("합성사람-항체 라이브러리")의 제조방법 및 용도
DE60231651D1 (de) Proteinreinigungsverfahren
ES2188583T3 (es) Polipeptidos para el virus de la hepatitis c (hcv).
FI942369A0 (fi) Hepatitis-C-virustesti
DK614987A (da) Syntetiske htlv-iii peptider, praeparater og anvendelser deraf
ATE171472T1 (de) Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
ES2138784T3 (es) Antigenos sinteticos para la deteccion de anticuerpos contra el virus de la hepatitis c.
ES2130121T3 (es) Antigeno intra-acrosomico de esperma humano para uso en una vacuna anticonceptiva.
DE69128273D1 (de) Für toxin b von clostridium difficile spezifische monoklonale antikörper
ES2173910T3 (es) Anticuerpos humanizados dirigidos contra el antigeno a33.
ES2118129T3 (es) Anticuerpos monoclonales contra las regiones de cubierta putativas del virus vhc y procedimientos de utilizacion de estos.
DK1002092T3 (da) Mimotoper af hypervariabel region 1 af E2-glycoproteinet fra HCV og anvendelser deraf
ATE178096T1 (de) Monoklonale antikörper gegen den hepatitis c- virus und verfahren diese zu benutzen
ES2126598T3 (es) Anticuerpos monoclonales que se fijan sobre las proteinas ns5 supuestas del virus de la hepatitis c, y procedimientos de utilizacion de estos anticuerpos.
ATE122895T1 (de) Monoklonale antikörper gegen den interleukin 2- rezeptor.
ES2013665A6 (es) Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 603307

Country of ref document: ES